Alpha -Tocopherol Acetate Dl- Ascorbic Acid Biotin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Acetate Dl- Ascorbic Acid Biotin
- Multi-Ingredient Nutritional Supplement: Drug Repurposing Evaluation Incomplete
Multi-Ingredient Nutritional Supplement: Drug Repurposing Evaluation Incomplete
One-Sentence Summary
This candidate is a multi-ingredient nutritional supplement combination containing twelve components — including Vitamin E, Vitamin C, Biotin, Calcium, Vitamin D3, Vitamin B12, DHA (Doconexent), Iron, Folic Acid, Magnesium, Iodine, and Vitamin B6 — which together resemble a prenatal or comprehensive multivitamin formulation.
The TxGNN model did not return any predicted new indications for this candidate, and the drug is currently not marketed in Taiwan with no registered licenses. A formal repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing prediction was generated by TxGNN for this candidate.
The combination consists of twelve nutritional ingredients (DL-α-Tocopherol Acetate, Ascorbic Acid, Biotin, Calcium Carbonate, Cholecalciferol, Cyanocobalamin, Doconexent, Ferrous Fumarate, Folic Acid, Magnesium Oxide, Potassium Iodide, Pyridoxine). Based on its composition — particularly the presence of Folic Acid, DHA (Doconexent), Iron, and Iodine — this combination is structurally consistent with a prenatal or antenatal nutritional supplement. Each component individually has well-characterised biological roles:
- Folic Acid + Cyanocobalamin (B12): prevention of neural tube defects and megaloblastic anaemia
- Doconexent (DHA): fetal neurological and retinal development
- Ferrous Fumarate: iron supplementation for gestational anaemia
- Cholecalciferol (D3) + Calcium + Magnesium: bone mineralisation and maternal calcium homeostasis
- Potassium Iodide: thyroid hormone synthesis during pregnancy
However, because TxGNN evaluates drugs as individual entities mapped to DrugBank IDs, and this candidate has no DrugBank ID and is represented as a compound multi-ingredient string, the model was unable to match it to any node in the knowledge graph. This is a pipeline-level limitation, not necessarily a scientific limitation of the individual components.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination as a unified repurposing candidate.
Literature Evidence
Currently no related literature available for this combination as a unified TxGNN candidate.
Taiwan Market Information
This drug combination has no registered licenses in Taiwan and is currently not marketed (未上市). No authorization records are available.
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were returned for this multi-ingredient combination query.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN returned no predicted indications for this candidate because the multi-ingredient compound string could not be resolved to a DrugBank node in the knowledge graph. Without a valid prediction, there is no repurposing signal to evaluate.
To proceed, the following is needed:
- Decompose the combination: Run TxGNN predictions individually for each of the twelve active ingredients (e.g., Doconexent, Folic Acid, Ferrous Fumarate) and aggregate results
- Resolve DrugBank ID: Map the combination or its key components to valid DrugBank IDs to enable knowledge graph traversal
- Clarify intended use case: If this is a prenatal supplement formulation, the evaluation framework may need to be adapted — repurposing analysis is most applicable to single-entity pharmaceutical drugs, not fixed nutritional combinations
- Obtain Taiwan regulatory data: Download the package insert PDF from the TFDA website to extract warnings and contraindications, once a matched product is identified
- Obtain MOA data: Query the DrugBank API for each individual component to support mechanism-based association analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.